Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Handb Exp Pharmacol. 2022;274:165-180. doi: 10.1007/164_2021_555.
Obesity is a major risk factor for the development of comorbidities such as type 2 diabetes, neurodegenerative disorders, osteoarthritis, cancer, cardiovascular and renal diseases. The onset of obesity is linked to an increase of senescent cells within adipose tissue and other organs. Cellular senescence is a stress response that has been shown to be causally linked to aging and development of various age-related diseases such as obesity. The senescence-associated-secretory phenotype of senescent cells creates a chronic inflammatory milieu that leads to local and systemic dysfunction. The elimination of senescent cells using pharmacological approaches (i.e., senolytics) has been shown to delay, prevent, or alleviate obesity-related organ dysfunction.
肥胖是多种合并症发展的一个主要风险因素,如 2 型糖尿病、神经退行性疾病、骨关节炎、癌症、心血管和肾脏疾病。肥胖的发生与脂肪组织和其他器官中衰老细胞的增加有关。细胞衰老是一种应激反应,已被证明与衰老和各种与年龄相关的疾病(如肥胖)的发展有因果关系。衰老细胞的衰老相关分泌表型会产生慢性炎症环境,导致局部和全身功能障碍。使用药理学方法(即衰老细胞清除剂)消除衰老细胞已被证明可延迟、预防或减轻肥胖相关的器官功能障碍。